Which Post-Delivery drug is safer for the heart? new study compares carbetocin and oxytocin

NCT ID NCT03899961

First seen Feb 13, 2026 · Last updated Jun 21, 2026 · Updated 16 times

Summary

This study compared two drugs, carbetocin and oxytocin, given to healthy pregnant women after delivery to prevent heavy bleeding. The goal was to see if one causes less heart strain than the other. 240 women participated, and researchers measured heart damage markers and side effects.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PREGNANCY COMPLICATIONS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Akershus University Hospital

    Lørenskog, Norway

  • Division of Anaesthesia and Intensive Care Medicine, Oslo University Hospital - Rikshospitalet

    Oslo, 0027, Norway

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Carbetocin and oxytocin (drugs given after childbirth to prevent bleeding)

What this could lead to

If carbetocin is safer for the heart, it could become the preferred drug for preventing bleeding after delivery, especially in women with heart conditions.

What could go wrong

This is a small, completed study in healthy women, so results may not apply to all pregnant women. Both drugs are already in use and considered safe, so major differences are unlikely.

Conditions

The condition(s) this trial relates to.

Hemorrhage pregnancy disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.